Eduard Z. Burnevich

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C

Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C

Journal: Terapevticheskii arkhiv

Published: April 16, 2020

Antiviral therapy of chronic hepatitis C: 30 years success story

Antiviral therapy of chronic hepatitis C: 30 years success story

Journal: Terapevticheskii arkhiv

Published: April 16, 2020

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial.

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial.

Journal: Hepatic medicine : evidence and research

Published: December 07, 2019

Risk factors of unfavorable prognosis of chronic hepatitis C.

Risk factors of unfavorable prognosis of chronic hepatitis C.

Journal: Terapevticheskii arkhiv

Published: May 17, 2019

Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.

Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.

Journal: Journal of viral hepatitis

Published: February 08, 2019

Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.

Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.

Journal: Infectious diseases (London, England)

Published: December 01, 2018

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.

Journal: World journal of gastroenterology

Published: December 22, 2017

Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection.

Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection.

Journal: Hepatology communications

Published: November 10, 2017

Letter: cure of chronic hepatitis B and D after 12 years of treatment with low-dose standard interferon alfa-2b.

Letter: cure of chronic hepatitis B and D after 12 years of treatment with low-dose standard interferon alfa-2b.

Journal: Alimentary pharmacology & therapeutics

Published: August 12, 2016

Simeprevir in combination with pegylated interferon-α and ribavirin in the treatment of naïve patients with genotype 1 chronic hepatitis C

Simeprevir in combination with pegylated interferon-α and ribavirin in the treatment of naïve patients with genotype 1 chronic hepatitis C

Journal: Terapevticheskii arkhiv

Published: February 27, 2015

Successful treatment of severe HCV-cryoglobulinemic vasculitis with the use of CD20 monoclonalantibodies and antiviral agents

Successful treatment of severe HCV-cryoglobulinemic vasculitis with the use of CD20 monoclonalantibodies and antiviral agents

Journal: Klinicheskaia meditsina

Published: January 01, 2014

Systemic manifestations of primary sclerosing cholangitis

Systemic manifestations of primary sclerosing cholangitis

Journal: Klinicheskaia meditsina

Published: July 25, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026